Healthcare Professionals
Other Medtronic CRT Devices
Cardiac resynchronization therapy (CRT) is a proven treatment for selected patients with heart failure-induced conduction disturbances and ventricular dyssynchrony. When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction.
Consulta CRT-D Device
A high-energy, wireless device with features that help to ensure CRT.
Key features include:
- Exclusive OptiVol Fluid Status Monitoring, clinically proven to predict worsening heart failure symptoms1-7
- Complete Capture Management for ensuring CRT therapy
- Sophisticated device diagnostics for help in assessing a patient’s clinical status
- Remote device follow-up with the exclusive Medtronic CareLink® Network
Important Safety Information
For CRT-D devices, certain programming and device operations may not provide cardiac resynchronization. Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters.
| Specifications | |
|---|---|
|
Volume |
38 cc |
|
Size (H x W x D) |
69 x 51 x 15 mm |
|
Mass |
68 g |
concerto II
Concerto II CRT-D
A high-energy, wireless device with features that help to ensure CRT.
Key features include:
- Exclusive OptiVol Fluid Status Monitoring, clinically proven to predict worsening heart failure symptoms 1-7
- Left ventricular capture management
- Sophisticated device diagnostics for help in assessing a patient’s clinical status
- Remote device follow-up with the exclusive Medtronic CareLink® Network
Important Safety Information
Changes in patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.
| Specifications | |
|---|---|
|
Volume |
38 cc |
|
Size (H x W x D) |
69 x 51 x 15 mm |
|
Mass |
68 g |
References
1
Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9,2005;112(6):841-848.
2
Vollmann D, Nägele H, Schauert P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
3
Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. PACE. March 2008;32(3):363-370.
4
Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
5
Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481.
6
Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. Vol. 15 No. 9 2009, p 813.
7
Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.
References
1
Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9,2005;112(6):841-848.
2
Vollmann D, Nägele H, Schauert P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
3
Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. PACE. March 2008;32(3):363-370.
4
Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
5
Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481.
6
Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. Vol.15 No. 9 2009, p 813.
7
Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.